1 Gold Mining Stock That's Winning Over Analysts Ahead of the next leg higher in the gold price rally, here’s a gold mining stock with increasingly optimistic ratings from Wall Street experts. Barchart · Jul 4, 2024
Analysts Continue To See Upside In Salesforce Post Q2 Beat Despite Challenging Macros Salesforce, Inc (NYSE:CRM) clocked 22% revenue growth to $7.72 billion in Q2, beating consensus. The EPS of $1.19 topped the consensus. The board approved a buyback of up to $10 billion. The Q3 and FY guidance were below the consensus. Mizuho analyst Gregg Moskowitz reiterated a Buy and cut the price target from $245 to $235.… Benzinga · Aug 25, 2022
Salesforce Faces Price Target Cuts On Guidance Cut, Shares Slide Salesforce Inc (NYSE: CRM) reported upbeat results for its second quarter, but lowered its annual projections. Benzinga · Aug 25, 2022
Looking At Microsoft's Recent Whale Trades A whale with a lot of money to spend has taken a noticeably bullish stance on Microsoft. Looking at options history for Microsoft (NASDAQ:MSFT) we detected 40 strange trades. Benzinga · Aug 1, 2022
Walmart To $142? Plus This Analyst Raises Price Target On McDonald's Keybanc raised the price target for McDonald's Corporation (NYSE: MCD) from $285 to $290. However, Keybanc analyst Eric Gonzalez maintained the stock with an Overweight rating. McDonald's shares fell 0.3% to $256.23 in pre-market trading. Benzinga · Jul 27, 2022
Benzinga · Jun 27, 2022 BMO Capital Maintains Outperform Rating for Micron Technology: Here's What You Need To Know BMO Capital has decided to maintain its Outperform rating of Micron Technology (NASDAQ:MU) and lower its price target from $115.00 to $85.00. Shares of Micron Technology are trading up 2.62% over the last 24 hours, at $59.97 per share.
Benzinga · Jun 24, 2022 Read How Analysts Reacted To Darden Restaurants' Q4 Results Wedbush analyst Nick Setyan lowered the price target on Darden Restaurants Inc (NYSE:DRI) to $122 (3% upside) from $140 and kept a Neutral rating on the shares. The analyst noted that FY23 guidance is predicated on normalization in inflation trends in the second half and has lowered his FY23 EPS estimate to $7.60 from $8.41…
Benzinga · Jun 23, 2022 BMO Capital Maintains Market Perform Rating for Century Aluminum: Here's What You Need To Know BMO Capital has decided to maintain its Market Perform rating of Century Aluminum (NASDAQ:CENX) and lower its price target from $14.00 to $9.00. Shares of Century Aluminum are trading down 14.52% over the last 24 hours, at $7.30 per share.
Benzinga · Jun 21, 2022 BMO Capital Maintains Market Perform Rating for Gartner: Here's What You Need To Know BMO Capital has decided to maintain its Market Perform rating of Gartner (NYSE:IT) and lower its price target from $315.00 to $265.00. Shares of Gartner are trading up 1.71% over the last 24 hours, at $234.27 per share. A move to $265.00 would account for a 13.12% increase from the…
Benzinga · Jun 17, 2022 BMO Capital Sees Almost 300% Upside On Centessa Stock BMO Capital has initiated coverage on Centessa Pharmaceuticals plc (NASDAQ:CNTA) with a price target of $19 (293% upside), and an Outperform rating. The analyst writes that ZF874 is a differentiated oral therapy as it addresses the root cause of AATD. Early ZF874 data (N=2) demonstrated therapeutic efficacy in patients, but liver toxicity was also flagged.…
Benzinga · Jun 17, 2022 BMO Initiates Coverage On This Gene Editing Spearhead BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ:NTLA) with a Market Perform rating and a $54 target price. The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies. But challenges around the lack of clarity around an IND approval in the U.S., ongoing CRISPR/Cas9 IP litigations with Editas Medicine Inc (NASDAQ:EDIT), and high patient…
Benzinga · Jun 17, 2022 BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ:BEAM) with a Market Perform rating and a price target of 41. BMO writes that it appreciates the high potential of Beam's next-generation editing approach, but clinical validation is yet to be established. Preclinical base editing data point to a favorable benefit/risk profile. Also Read: Pfizer, Beam…
Benzinga · Jun 17, 2022 BMO Capital & Credit Suisse Slash United States Steel Price Target - Read Why BMO Capital analyst David Gagliano lowered the price target on United States Steel Corp (NYSE:X) to $23 (an upside of 15.5%) from $30 while maintaining the Market Perform rating on the shares. X provided its 'mid-quarter' update yesterday and mentioned that it expects 2Q22 EBITDA of $1.6 billion, vs. BMO/FactSet consensus of $1.5 billion. Related: United…
Benzinga · Jun 17, 2022 BMO Capital Maintains Market Perform Rating for United States Steel: Here's What You Need To Know BMO Capital has decided to maintain its Market Perform rating of United States Steel (NYSE:X) and lower its price target from $30.00 to $23.00. Shares of United States Steel are trading up 1.76% over the last 24 hours, at $19.93 per share.
Benzinga · Jun 16, 2022 'That Made Me Look Closer': Why This Adobe Investor Is Cautious Ahead Of Q2 Earnings Adobe Inc (NASDAQ: ADBE) is set to announce its quarterly results after the bell Thursday, and one investor sees warning signs ahead of the report.